Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
KM Biologics’s Smallpox Vaccine Up for Review for Monkeypox Use
A key health ministry advisory committee will discuss whether to add a monkeypox indication to KM Biologics’s freeze-dried smallpox vaccine LC16 “KMB” at its meeting on July 29. The WHO has declared the monkeypox outbreak to be a global health…
To read the full story
Related Article
- MHLW Reports 1st Mpox Death in Japan, Man in 30s
December 14, 2023
- MHLW Starts Clinical Study on Mpox Vaccine for People with High Infection Risks
June 19, 2023
- Mpox Cases Hit 120 in Japan: MHLW
April 27, 2023
- Number of Mpox Cases Totals 109 in Japan: MHLW
April 17, 2023
- Mpox Cases Top 100 in Japan, 10 New Patients Confirmed
April 13, 2023
- Japan Approves KM Biologics’ Smallpox Vaccine for Monkeypox
August 2, 2022
- MHLW Presents Plan for Monkeypox Vaccinations with KM Biologics’ Jab
August 2, 2022
- KM Biologics’s Smallpox Vaccine in Line to Add Monkeypox Use
August 1, 2022
- Japan Detects 2nd Monkeypox Case in Tokyo
July 29, 2022
- Taisho/Ablynx’s RA Med, BI’s Psoriasis Drug Up for MHLW Panel Review on July 29
July 19, 2022
- Japan Begins TPOXX Clinical Research as It Braces for Monkeypox Outbreak
June 30, 2022
REGULATORY
- Voranigo and More Meds Missing from April Listing Slate; Servier Plans Packaging Change
April 10, 2026
- Health Insurance Reform Bill Enters Diet Debate; OTC-Like Drug Charges in Focus
April 10, 2026
- CEPI Seeks Continued Technology, Funding Ties with Japan
April 10, 2026
- Dialysis Tubing and Medical Device Makers Fret over Long-Term Supply Risks
April 10, 2026
- Japan Moves to Bypass Wholesalers in Fuel Supply to Hospitals
April 10, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…